MBCC 2011 article list

Article

CancerNetwork presents coverage of the most important information to come out of this year's Miami Breast Cancer Conference.
 

More Coverage

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
1 expert is featured in this series.
2 experts are featured in this series.
Related Content
FLEX study findings show that the MammaPrint Index was predictive of 5-year DRFI for endocrine therapy with or without chemotherapy in early breast cancer.

MammaPrint Displays Predictive Utility for Chemo in HR+/HER2– Breast Cancer

Roman Fabbricatore
August 13th 2025
Article
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 13th 2025
Podcast
This was the first trial for patients with late-stage WM to show the potential for complete responses with a chemotherapy-free immunotherapy.

Novel CD19 CAR-NK Therapy Yields Responses in Waldenstrom Macroglobulinemia

Tim Cortese
August 13th 2025
Article
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 13th 2025
Podcast
The drug that the companion diagnostic identifies patients for, zongertinib, received FDA approval for HER2-mutant NSCLC on August 8, 2025.

FDA Approves NGS-Based Companion Diagnostic for Zongertinib in NSCLC

Roman Fabbricatore
August 13th 2025
Article
This is the first and only therapy that improved survival when used before and after standard of care surgery in patients who are cisplatin-ineligible with MIBC.

Enfortumab Vedotin/Pembrolizumab Improved Survival Vs Surgery in MIBC

Tim Cortese
August 13th 2025
Article